uniQure NV (QURE) Receives a Buy from Cantor Fitzgerald

Cantor Fitzgerald analyst Elemer Piros maintained a Buy rating on uniQure NV (NASDAQ: QURE) today and set a price target of $58. The company’s shares opened today at $33.50.

Piros wrote:

“We rate uniQure Overweight. uniQure focuses on the development of gene therapy products for patients suffering from severe genetic diseases. uniQure is in Phase 3 development for the treatment of hemophilia B with AMT-061, and has additional preclinical programs for Huntington’s disease, hemophilia A and cardiovascular disease.”

According to TipRanks.com, Piros is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -2.6% and a 46.3% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.

uniQure NV has an analyst consensus of Strong Buy, with a price target consensus of $52, which is a 55.2% upside from current levels. In a report issued on September 24, H.C. Wainwright also maintained a Buy rating on the stock with a $48 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $43.23 and a one-year low of $9.47. Currently, uniQure NV has an average volume of 267.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded on January 9, 2012 and is headquartered in Amsterdam, the Netherlands.